Last reviewed · How we verify
Dipropylacetamide (VALPROMIDE)
Dipropylacetamide (generic name: VALPROMIDE) is a valpromide drug. It is currently in Phase 2 development.
Valpromide works by modulating the activity of certain neurotransmitters in the brain.
Dipropylacetamide is an anti-epileptic drug that has been studied in clinical trials for the treatment of epilepsy. It has also been investigated in relation to drug hypersensitivity syndrome.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | VALPROMIDE |
|---|---|
| Drug class | valpromide |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Think of neurotransmitters like messengers that help different parts of the brain talk to each other. Valpromide helps regulate the amount of these messengers, which can help balance brain activity and treat certain conditions. By doing so, it can help reduce symptoms of anxiety, depression, and other mental health conditions.
Approved indications
Common side effects
- Poisoning deliberate
- Coma
- Hypothermia
- Toxicity to various agents
- Suicide attempt
- Meningioma
- Hepatocellular injury
- Alkalosis hypochloraemic
- Bradycardia
- Hypometabolism
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dipropylacetamide CI brief — competitive landscape report
- Dipropylacetamide updates RSS · CI watch RSS
Frequently asked questions about Dipropylacetamide
What is Dipropylacetamide?
How does Dipropylacetamide work?
What is the generic name of Dipropylacetamide?
What drug class is Dipropylacetamide in?
What development phase is Dipropylacetamide in?
What are the side effects of Dipropylacetamide?
Related
- Drug class: All valpromide drugs
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing